HOME >> BIOLOGY >> NEWS
Sequence matters when using novel agent

TORONTO - An experimental agent that targets a cancer cell's protein shredding machinery (the proteasome) should be given either before or with taxane-based chemotherapy drugs, but not after, say researchers at The University of Texas M. D. Anderson Cancer Center who conducted laboratory tests using prostate cancer cells.

The finding is important because the new therapy, known as PS-341 (Velcade), will likely be tried as new treatment for a number of cancers due to its effectiveness in multiple myeloma, says Christos Papandreou, M.D., Ph.D., assistant professor in the department of Genitourinary Medical Oncology.

"It appears PS-341 could become quite a hit as a novel proteasome inhibitor, a drug that increases the effectiveness of chemotherapy agents," Papandreou says. "We know that while the sequence it is used in doesn't matter with certain classes of chemotherapy drugs, it does with others. Hopefully, future clinical trials will reflect this new understanding."

The findings were published in the Proceedings for the 2003 Annual Meeting of the American Association for Cancer Research.

Last summer, the agent demonstrated a dramatic success when used to treat patients with multiple myeloma. Researchers at Dana-Farber Cancer Institute, where it was tested, said 70 percent of 78 patients with advanced multiple myeloma improved - an unheard of benefit in that disease. The agent is now being used in a Phase II clinical trial in advanced prostate cancer, and several Phase I clinical trials are underway, or have been completed, testing PS-341 in pancreatic, lung and colorectal cancers.

The drug is designed to specifically inhibit proteasomes, the cell's enzymatic protein-shredding machinery, responsible for breaking down a variety of proteins, including many that regulate cell division.

M. D. Anderson researchers designed experiments in which they treated prostate cancer cells with PS-341 alone or in combination with
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
9-Apr-2003


Page: 1 2

Related biology news :

1. Sequence of human chromosome 7 is fine-tuned and finished
2. Sequenced malaria genome exposes novel drug targets
3. Sequence provides insights into a pathogens virulence mechanism allowing for vaccine development
4. New Science Press launches Proteins: From Sequence to Structure
5. Sequencers take a bird in hand
6. Genetic Stowaways May Contribute To Evolutionary Change: Adjacent Sequences Tag Along With Mobile DNA Elements, Study Shows
7. Scientists Sequence Chlamydia Trachomatis Genome
8. New Insights On Sequence of Cell Death After Brain Injury: Understanding Cellular Events After Brain Trauma Could Lead To Better Therapies
9. Syphilis Genome Sequence Offers Clues To Better Diagnosis, Prevention And Treatment
10. Why some animals have smaller eyes: Lifestyle matters
11. Why genetic diversity matters

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/19/2020)... Fla. (PRWEB) , ... March 19, 2020 , ... The ... his talents as host to the informational show "In Depth". The TV program highlights ... "In Depth" is shifting gears on a new episode with a dive into the ...
(Date:3/13/2020)... ... 13, 2020 , ... According to the American Academy of ... possibly be transmitted by aerosol or direct contact with the conjunctiva, the superficial ... precautions to avoid contracting the coronavirus. Touching the eyes while inserting contact lenses ...
(Date:3/11/2020)... ... March 11, 2020 , ... ... company backed by Siemens Healthineers and several healthcare VC firms introduces a first ... people in over 100 countries and has caused over 4,000 fatalities to date. ...
Breaking Biology News(10 mins):
(Date:3/4/2020)... ... ... This month, Cognosante will make its annual appearance at the HIMSS Global Health ... offerings that align with the HIMSS annual theme, “Be the Change.” , Cognosante’s ... From Interoperability and HIE to Cloud Computing and ...
(Date:2/26/2020)... ... 25, 2020 , ... Continuing its leading research on human ... its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) HMO. , 3-FL ... carbohydrates are indigestible and therefore function as a prebiotic by promoting early microbial ...
(Date:2/21/2020)... ... February 21, 2020 , ... Pharmaceutical ... operations in order to adapt to new approaches like ‘Industry 4.0’ and continuous ... demand for personalized medicine and therapies. But with an industry with the world’s ...
(Date:2/11/2020)... ... February 11, 2020 , ... INSPAN ... a long-term follow-up clinical study of outpatient L4-L5 lumbar interspinous fixation for ... extension block design, the Inspan device fixates the spine to allow for ...
Breaking Biology Technology:
Cached News: